Clinical Trials
2 trialsNCT05215548 2025-02-19
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
National Taiwan University Hospital
Phase 2 Active not recruiting
NCT04201756 2022-12-23
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Completed